Vancouver, Canada – February 4, 2025 – Onco-Innovations Limited (CSE: ONCO) (Frankfurt: W1H,WKN: A3EKSZ) (“Onco” or the “Company“) applauds the Lundin Cancer Fund for its generous $4 million donation to the Canadian Cancer Society to establish a pan-Canadian glioblastoma research program. This contribution marks the largest philanthropic gift ever received by the Canadian Cancer Society for glioblastoma research. [1]

The $4 million donation from the Lundin Cancer Fund will enable the Canadian Cancer Society to establish a pan-Canadian glioblastoma research program, focusing on accelerating research efforts to develop new treatment options for one of the most aggressive and difficult-to-treat forms of brain cancer. This initiative aims to bring together top researchers across the country, fostering collaboration and driving innovation in glioblastoma treatment. Together, the organizations also intend to raise an additional $4 million, for a total of $8 million, to transform brain cancer outcomes. In honour of Mr. Lukas Lundin, and to further support this initiative, two of Vancouver’s fundraising events—the Canadian Cancer Society Daffodil Ball and the Lundin Cancer Fund Gala—will come together in 2025 for a united effort to advance brain cancer research.[2]

Onco-Innovations applauds this significant contribution, recognizing its potential to make a meaningful impact in the fight against cancer. Investments like this not only advance scientific research but also provide hope for patients and families affected by glioblastoma.

Additionally, the Company announces that it has extended the term of its engagement with MCS Market Communication Service GmbH (business address: Rheinpromenade 13, 40789 Monheim am Rhein, Nordrhein-Westfalen, Deutschland, email: info@mcsmarket.de; telephone: +491772481220; and website: www.mcsmarket.de) (“MCS”) for the continued provision of a range of online marketing services, including campaign creation, production of marketing materials, as well as research and analytics (the “Services”).  The Services will continue and are expected to run until June 2025, or until budget exhaustion.  The Company has paid MCS EUR 500,000 for the extended term of Services, and no securities have been provided to MCS or its principals as compensation. The Services will be executed via digital channels, including Google Ads and native advertising.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to prevent and cure cancer through pioneering research and innovative solutions. The Company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco’s commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

“Thomas O’Shaughnessy”

Chief Executive Officer

For more information, please contact:

Thomas O’Shaughnessy

Chief Executive Officer

Tel: + 1 888 261 8055

investors@oncoinnovations.com

oncoinnovations.com

The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.

Forward-Looking Statements Caution. This news release may contain forward-looking statements, including in relation to the prospects of the Company, and the Company’s business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “potential”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

[1] https://www.bnnbloomberg.ca/investment-trends/2025/02/03/lundin-cancer-fund-contributes-4-million-to-the-canadian-cancer-society-to-establish-pan-canadian-glioblastoma-research-program/

[2] https://www.bnnbloomberg.ca/investment-trends/2025/02/03/lundin-cancer-fund-contributes-4-million-to-the-canadian-cancer-society-to-establish-pan-canadian-glioblastoma-research-program/